​

LENZ Therapeutics (LENZ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LENZ Stock Forecast

LENZ Therapeutics (LENZ) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 59.57% increase from the last price of $7.52.

$5 $12 $19 $26 $33 $40 High: $12 Avg: $12 Low: $12 Last Closed Price: $7.52

LENZ Stock Rating

LENZ Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

LENZ Price Target Upside V Benchmarks

TypeNameUpside
StockLENZ Therapeutics59.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$12.00$12.00$45.00
Last Closing Price$7.52$7.52$7.52
Upside/Downside59.57%59.57%498.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 2616---7
Apr, 2616---7
Mar, 2616---7
Feb, 2616---7
Jan, 2616---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 12, 2026Piper Sandler$12.00$9.9920.12%59.57%
Oct 27, 2025Matthew CaufieldH.C. Wainwright$56.00$30.8781.41%644.68%
Oct 10, 2025Piper Sandler$67.00$46.2544.86%790.96%
Apr 14, 2025Biren AminPiper Sandler$51.00$23.24119.45%578.19%
Aug 15, 2024Joseph CatanzaroPiper Sandler$36.00$22.2561.80%378.72%
Aug 15, 2024Yigal NochomovitzCitigroup$32.00$23.5036.17%325.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 12, 2026H.C. WainwrightBuyBuyhold
May 12, 2026Piper SandlerOverweightNeutraldowngrade
Mar 26, 2026CitigroupBuyBuyhold
Mar 10, 2026William BlairOutperformOutperformhold
Dec 15, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 10, 2025Piper SandlerOverweightOverweighthold
Jul 31, 2025CitigroupBuyBuyhold
Jul 28, 2025H.C. WainwrightBuyBuyhold
Sep 26, 2024Raymond JamesOutperforminitialise

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-15.30$-2.34$-2.85---
Avg Forecast$-12.25$-2.82$-2.38$-2.21$-0.33$1.46
High Forecast$-6.44$-2.60$-2.00$-1.16$-0.17$2.25
Low Forecast$-18.95$-2.95$-2.93$-3.41$-0.50$0.77
Surprise %24.90%-17.02%19.75%---

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$19.09M---
Avg Forecast--$8.19M$52.04M$125.68M$198.22M
High Forecast--$11.84M$73.92M$178.52M$281.56M
Low Forecast--$5.30M$33.05M$79.83M$125.90M
Surprise %--132.96%---

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-69.97M$-49.77M$-82.13M---
Avg Forecast$-99.78M$-22.99M$-19.40M$-17.98M$-2.65M$11.87M
High Forecast$-52.46M$-21.20M$-16.27M$-9.45M$-1.39M$18.36M
Low Forecast$-154.32M$-24.05M$-23.83M$-27.81M$-4.09M$6.24M
Surprise %-29.88%116.45%323.38%---

LENZ Forecast FAQ

Is LENZ Therapeutics stock a buy?

LENZ Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that LENZ Therapeutics is a favorable investment for most analysts.

What is LENZ Therapeutics's price target?

LENZ Therapeutics's price target, set by 5 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 59.57% change from the previous closing price of $7.52.

How does LENZ Therapeutics stock forecast compare to its benchmarks?

LENZ Therapeutics's stock forecast shows a 59.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for LENZ Therapeutics over the past three months?

  • May 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is LENZ Therapeutics’s EPS forecast?

LENZ Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.21, marking a -22.46% decrease from the reported $-2.85 in 2025. Estimates for the following years are $-0.33 in 2027, and $1.46 in 2028.

What is LENZ Therapeutics’s revenue forecast?

LENZ Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $52.04M, reflecting a 172.63% increase from the reported $19.09M in 2025. The forecast for 2027 is $125.68M, and $198.22M for 2028.

What is LENZ Therapeutics’s net income forecast?

LENZ Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-17.984M, representing a -78.10% decrease from the reported $-82.127M in 2025. Projections indicate $-2.647M in 2027, and $11.87M in 2028.